ASCENTAGE PHARMA GROUP INTERNATIONAL

AAPGNasdaq

Healthcare · Pharmaceutical Preparations · E9 · SEC filings ↗ · Compare ⊕

Financials

SEC XBRL · annual

No structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).

Insider transactions

SEC Form 4 · most recent

2 acquisitions0 disposalsnet +188,321 shares · last 2

Insider	Date	Type	Shares	Price
Zhai YifanOfficer — Chief Medical Officer	May 21, 2026	Option exercise	92,746	$0.00
Yang DajunOfficer — Chairman and CEO	May 21, 2026	Option exercise	95,575	$0.00

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly

Settlement	Shares short	Days to cover	Δ vs prior
May 15, 2026	596	1.0	+3625.0%
Apr 30, 2026	16	1.0	-97.8%
Apr 15, 2026	719	1.0	-51.1%
Mar 31, 2026	1,470	1.0	+54.6%
Mar 13, 2026	951	1.0	+546.9%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Recent SEC filings

All filings ↗

6-KREPORT OF FOREIGN PRIVATE ISSUERJun 1, 2026
6-KCURRENT REPORTMay 28, 2026
6-KREPORT OF FOREIGN PRIVATE ISSUERMay 28, 2026
4PRIMARY DOCUMENTMay 22, 2026
4PRIMARY DOCUMENTMay 22, 2026
6-KREPORT OF FOREIGN PRIVATE ISSUERMay 22, 2026
6-KREPORT OF FOREIGN PRIVATE ISSUERMay 13, 2026
6-KREPORT OF FOREIGN PRIVATE ISSUERMay 12, 2026
6-KREPORT OF FOREIGN PRIVATE ISSUERMay 1, 2026
20-FANNUAL REPORTApr 29, 2026
6-KREPORT OF FOREIGN PRIVATE ISSUERApr 22, 2026
4PRIMARY DOCUMENTApr 21, 2026
3PRIMARY DOCUMENTApr 21, 2026
3/APRIMARY DOCUMENTApr 20, 2026
6-KREPORT OF FOREIGN PRIVATE ISSUERApr 20, 2026

Event-driven situations (1)

Dec 27, 2024IPOcompleted

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.